Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program - 19/09/18
Doi : 10.1016/j.jaad.2018.06.024
Kelsey A. Orrell, MB, BCh, BAO, Morgan Murphrey, BS, Ryan C. Kelm, BS, Harrison H. Lee, BS, David R. Pease, BS, Anne E. Laumann, MBChB, MRCP, Dennis P. West, PhD, Beatrice Nardone, MD, PhD ⁎ 
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
∗Correspondence to: Beatrice Nardone, MD, PhD, Department of Dermatology, Northwestern University, 676 N Saint Clair St, Ste 1600, Chicago, IL 60611Department of DermatologyNorthwestern University676 N Saint Clair St, Ste 1600ChicagoIL60611
| Funding sources: Northwestern Medicine Enterprise Data Warehouse is supported by the National Institutes of Health's National Center for Advancing Translational Sciences grant number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 4
P. 777-778 - octobre 2018 Retour au numéro
Article précédent
- Epidemiology of staphylococcal scalded skin syndrome in US adults
- Alanna Staiman, Derek Y. Hsu, Jonathan I. Silverberg
- Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study
- Hyun Jeong Ju, Ki-Jo Kim, Dae Suk Kim, Ji Hae Lee, Gyung Moon Kim, Chul Jong Park, Jung Min Bae
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?